Top

Published in:

01-06-2013

Mouse models of BRCA1 and their application to breast cancer research

Authors: Jennifer Dine, Chu-Xia Deng

Published in: Cancer and Metastasis Reviews | Issue 1-2/2013

Abstract

Germline mutations of human breast cancer-associated gene 1 (BRCA1) predispose women to breast and ovarian cancers. In mice, over 20 distinct mutations, including null, hypomorphic, isoform, conditional, and point mutations, have been created to study functions of Brca1 in mammary development and tumorigenesis. Analyses using these mutant mice have yielded an enormous amount of information that greatly facilitates our understanding of the gender- and tissue-specific tumor suppressor functions of BRCA1, as well as enriches our insights into applying these preclinical models of disease to breast cancer research. Here, we review features of these mutant mice and their applications to cancer prevention and therapeutic treatment.

DeSantis, C., Siegel, R., Bandi, P., & Jemal, A. (2011). Breast cancer statistics, 2011. CA: a Cancer Journal for Clinicians, 61, 409–418.CrossRef

Hall, J. M., Lee, M. K., Newman, B., Morrow, J. E., Anderson, L. A., Huey, B., & King, M. C. (1990). Linkage of early-onset familial breast cancer to chromosome 17q21. Science, 250, 1684–1689.PubMedCrossRef

Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266, 66–71.PubMedCrossRef

Alberg, A. J., & Helzlsouer, K. J. (1997). Epidemiology, prevention, and early detection of breast cancer. Current Opinion in Oncology, 9, 505–511.PubMedCrossRef

Brody, L. C., & Biesecker, B. B. (1998). Breast cancer susceptibility genes. BRCA1 and BRCA2. Medicine (Baltimore), 77, 208–226.CrossRef

Eccles, D. M., & Pichert, G. (2005). Familial non-BRCA1/BRCA2-associated breast cancer. The Lancet Oncology, 6, 705–711.PubMedCrossRef

Zhang, J., & Powell, S. N. (2005). The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Molecular Cancer Research, 3, 531–539.PubMedCrossRef

Lane, T. F., Deng, C., Elson, A., Lyu, M. S., Kozak, C. A., & Leder, P. (1995). Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice. Genes & Development, 9, 2712–2722.CrossRef

ElShamy, W. M., & Livingston, D. M. (2004). Identification of BRCA1-IRIS, a BRCA1 locus product. Nature Cell Biology, 6, 954–967. Epub 2004 Sep 2026.PubMedCrossRef

10.

Thakur, S., Zhang, H. B., Peng, Y., Le, H., Carroll, B., Ward, T., Yao, J., Farid, L. M., Couch, F. J., Wilson, R. B., & Weber, B. L. (1997). Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Molecular and Cellular Biology, 17, 444–452.PubMed

11.

Wilson, C. A., Payton, M. N., Elliott, G. S., Buaas, F. W., Cajulis, E. E., Grosshans, D., Ramos, L., Reese, D. M., Slamon, D. J., & Calzone, F. J. (1997). Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b. Oncogene, 14, 1–16.PubMedCrossRef

12.

Xu, X., Weaver, Z., Linke, S. P., Li, C., Gotay, J., Wang, X. W., Harris, C. C., Ried, T., & Deng, C. X. (1999). Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Molecular Cell, 3, 389–395.PubMedCrossRef

13.

Paterson, J. W. (1998). BRCA1: a review of structure and putative functions. Disease Markers, 13, 261–274.PubMed

14.

Deng, C. X. (2006). BRCA1: cell cycle checkpoint, genetic instability, DNA damage response, and cancer evolution. Nucleic Acids Research, 34, 1416–1426.PubMedCrossRef

15.

Deng, C. X., & Brodie, S. G. (2000). Roles of BRCA1 and its interacting proteins. Bioessays, 22, 728–737.PubMedCrossRef

16.

Deng, C. X. (2002). Tumor formation in Brca1 conditional mutant mice. Environmental and Molecular Mutagenesis, 39, 171–177.PubMedCrossRef

17.

Deng, C. X., & Wang, R. H. (2003). Roles of BRCA1 in DNA damage repair: a link between development and cancer. Human Molecular Genetics, 12, R113–R123.PubMedCrossRef

18.

Diaz-Cruz, E. S., Cabrera, M. C., Nakles, R., Rutstein, B. H., & Furth, P. A. (2010). BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer. Breast Disease, 32, 85–97.PubMed

19.

Drost, R. M., & Jonkers, J. (2009). Preclinical mouse models for BRCA1-associated breast cancer. British Journal of Cancer, 101, 1651–1657.PubMedCrossRef

20.

Hu, Y. (2009). BRCA1, hormone, and tissue-specific tumor suppression. International Journal of Biological Sciences, 5, 20–27.PubMedCrossRef

21.

Roy, R., Chun, J., & Powell, S. N. (2012). BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nature Reviews. Cancer, 12, 68–78.CrossRef

22.

Venkitaraman, A. R. (2002). Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell, 108, 171–182.PubMedCrossRef

23.

Capecchi, M. R. (1989). Altering the genome by homologous recombination. Science, 244, 1288–1292 [Review].PubMedCrossRef

24.

Xu, X., Li, C., Garrett-Beal, L., Larson, D., Wynshaw-Boris, A., & Deng, C. X. (2001). Direct removal in the mouse of a floxed neo gene from a three-loxP conditional knockout allele by two novel approaches. Genesis, 30, 1–6.PubMedCrossRef

25.

Hakem, R., de la Pompa, J. L., Elia, A., Potter, J., & Mak, T. W. (1997). Partial rescue of Brca1 (5–6) early embryonic lethality by p53 or p21 null mutation. Nature Genetics, 16, 298–302.PubMedCrossRef

26.

Ludwig, T., Chapman, D. L., Papaioannou, V. E., & Efstratiadis, A. (1997). Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes & Development, 11, 1226–1241.CrossRef

27.

Shen, S. X., Weaver, Z., Xu, X., Li, C., Weinstein, M., Chen, L., Guan, X. Y., Ried, T., & Deng, C. X. (1998). A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene, 17, 3115–3124.PubMedCrossRef

28.

Ludwig, T., Fisher, P., Ganesan, S., & Efstratiadis, A. (2001). Tumorigenesis in mice carrying a truncating Brca1 mutation. Genes & Development, 15, 1188–1193.CrossRef

29.

Kim, S. S., Cao, L., Lim, S. C., Li, C., Wang, R. H., Xu, X., Bachelier, R., & Deng, C. X. (2006). Hyperplasia and spontaneous tumor development in the gynecologic system in mice lacking the BRCA1-Delta11 isoform. Molecular and Cellular Biology, 26, 6983–6992.PubMedCrossRef

30.

Xu, X., Qiao, W., Linke, S. P., Cao, L., Li, W. M., Furth, P. A., Harris, C. C., & Deng, C. X. (2001). Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nature Genetics, 28, 266–271.PubMedCrossRef

31.

Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Jr., Butel, J. S., & Bradley, A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature, 356, 215–221.PubMedCrossRef

32.

Bachelier, R., Xu, X., Wang, X., Li, W., Naramura, M., Gu, H., & Deng, C. X. (2003). Normal lymphocyte development and thymic lymphoma formation in Brca1 exon 11-deficient mice. Oncogene, 22, 528–537.PubMedCrossRef

33.

Cao, L., Li, W., Kim, S., Brodie, S. G., & Deng, C. X. (2003). Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform. Genes & Development, 17, 201–213.CrossRef

34.

Cao, L., Xu, X., Cao, L. L., Wang, R. H., Coumoul, X., Kim, S. S., & Deng, C. X. (2007). Absence of full-length Brca1 sensitizes mice to oxidative stress and carcinogen-induced tumorigenesis in the esophagus and forestomach. Carcinogenesis, 28, 1401–1407.PubMedCrossRef

35.

Crook, T., Brooks, L. A., Crossland, S., Osin, P., Barker, K. T., Waller, J., Philp, E., Smith, P. D., Yulug, I., Peto, J., Parker, G., Allday, M. J., Crompton, M. R., & Gusterson, B. A. (1998). p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene, 17, 1681–1689.PubMedCrossRef

36.

Crook, T., Crossland, S., Crompton, M. R., Osin, P., & Gusterson, B. A. (1997). p53 mutations in BRCA1-associated familial breast cancer. Lancet, 350, 638–639.PubMedCrossRef

37.

Bunting, S. F., Callen, E., Wong, N., Chen, H. T., Polato, F., Gunn, A., Bothmer, A., Feldhahn, N., Fernandez-Capetillo, O., Cao, L., Xu, X., Deng, C. X., Finkel, T., Nussenzweig, M., Stark, J. M., & Nussenzweig, A. (2010). 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell, 141, 243–254.PubMedCrossRef

38.

Cao, L., Kim, S., Xiao, C., Wang, R. H., Coumoul, X., Wang, X., Li, W., Xu, X., De Soto, J., Takai, H., Mai, S., Elledge, S. J., Motoyama, N., & Deng, C. (2006). ATM-Chk2-p53 activation prevents tumorigenesis at an expense of organ homeostasis upon Brca1 deficiency. EMBO Journal, 25, 2167–2177.PubMedCrossRef

39.

Cao, L., Xu, X., Bunting, S. F., Liu, J., Wang, R. H., Cao, L. L., Wu, J. J., Peng, T. N., Chen, J., Nussenzweig, A., Deng, C. X., & Finkel, T. (2009). A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Molecular Cell, 35, 534–541.PubMedCrossRef

40.

Bunting, S. F., Callen, E., Kozak, M. L., Kim, J. M., Wong, N., Lopez-Contreras, A. J., Ludwig, T., Baer, R., Faryabi, R. B., Malhowski, A., Chen, H. T., Fernandez-Capetillo, O., D’Andrea, A., & Nussenzweig, A. (2012). BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. Molecular Cell, 46(2), 125–135.PubMedCrossRef

41.

Xu, X., Wagner, K. U., Larson, D., Weaver, Z., Li, C., Ried, T., Hennighausen, L., Wynshaw-Boris, A., & Deng, C. X. (1999). Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nature Genetics, 22, 37–43 [see comments].PubMedCrossRef

42.

Wagner, K. U., Wall, R. J., St-Onge, L., Gruss, P., Wynshaw-Boris, A., Garrett, L., Li, M., Furth, P. A., & Hennighausen, L. (1997). Cre-mediated gene deletion in the mammary gland. Nucleic Acids Research, 25, 4323–4330.PubMedCrossRef

43.

Weaver, Z., Montagna, C., Xu, X., Howard, T., Gadina, M., Brodie, S. G., Deng, C. X., & Ried, T. (2002). Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene, 21, 5097–5107.PubMedCrossRef

44.

Wang, R. H., Yu, H., & Deng, C. X. (2004). A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint. Proceedings of the National Academy of Sciences of the United States of America, 101, 17108–17113.PubMedCrossRef

45.

Nanda, R. (2011). “Targeting” triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers. Seminars in Oncology, 38, 254–262.PubMedCrossRef

46.

Rastelli, F., Biancanelli, S., Falzetta, A., Martignetti, A., Casi, C., Bascioni, R., Giustini, L., & Crispino, S. (2010). Triple-negative breast cancer: current state of the art. Tumori, 96, 875–888.PubMed

47.

Cortez, D., Wang, Y., Qin, J., & Elledge, S. J. (1999). Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science, 286, 1162–1166.PubMedCrossRef

48.

Lou, Z., Chini, C. C., Minter-Dykhouse, K., & Chen, J. (2003). Mediator of DNA damage checkpoint protein 1 regulates BRCA1 localization and phosphorylation in DNA damage checkpoint control. Journal of Biological Chemistry, 278, 13599–13602.PubMedCrossRef

49.

Zhou, B. B., & Elledge, S. J. (2000). The DNA damage response: putting checkpoints in perspective. Nature, 408, 433–439.PubMedCrossRef

50.

Kim, S. S., Cao, L., Baek, H. J., Lim, S. C., Li, C., Wang, R. H., Xu, X., Cho, K. H., & Deng, C. X. (2009). Impaired skin and mammary gland development and increased gamma-irradiation-induced tumorigenesis in mice carrying a mutation of S1152-ATM phosphorylation site in Brca1. Cancer Research, 69, 9291–9300.PubMedCrossRef

51.

Kim, S. S., Cao, L., Li, C., Xu, X., Huber, L. J., Chodosh, L. A., & Deng, C. X. (2004). Uterus hyperplasia and increased carcinogen-induced tumorigenesis in mice carrying a targeted mutation of the Chk2 phosphorylation site in Brca1. Molecular and Cellular Biology, 24, 9498–9507.PubMedCrossRef

52.

Chang, S., Biswas, K., Martin, B. K., Stauffer, S., & Sharan, S. K. (2009). Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations. The Journal of Clinical Investigation, 119, 3160–3171.PubMedCrossRef

53.

Deng, C. X. (2002). Roles of BRCA1 in centrosome duplication. Oncogene, 21, 6222–6227.PubMedCrossRef

54.

Turner, J. M., Aprelikova, O., Xu, X., Wang, R., Kim, S., Chandramouli, G. V., Barrett, J. C., Burgoyne, P. S., & Deng, C. X. (2004). BRCA1, histone H2AX phosphorylation, and male meiotic sex chromosome inactivation. Current Biology, 14, 2135–2142.PubMedCrossRef

55.

Xu, X., Aprelikova, O., Moens, P., Deng, C. X., & Furth, P. A. (2003). Impaired meiotic DNA-damage repair and lack of crossing-over during spermatogenesis in BRCA1 full-length isoform deficient mice. Development, 130, 2001–2012.PubMedCrossRef

56.

Monteiro, A. N. (2003). BRCA1: the enigma of tissue-specific tumor development. Trends in Genetics, 19, 312–315.PubMedCrossRef

57.

Elledge, S. J., & Amon, A. (2002). The BRCA1 suppressor hypothesis: an explanation for the tissue-specific tumor development in BRCA1 patients. Cancer Cell, 1, 129–132.PubMedCrossRef

58.

Trauernicht, A. M., & Boyer, T. G. (2003). BRCA1 and estrogen signaling in breast cancer. Breast Disease, 18, 11–20.PubMed

59.

Calderon-Margalit, R., & Paltiel, O. (2004). Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature. International Journal of Cancer, 112, 357–364.CrossRef

60.

Gadducci, A., Biglia, N., Sismondi, P., & Genazzani, A. R. (2005). Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer. Gynecological Endocrinology, 20, 343–360.PubMedCrossRef

61.

Prall, O. W., Rogan, E. M., & Sutherland, R. L. (1998). Estrogen regulation of cell cycle progression in breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology, 65, 169–174.PubMedCrossRef

62.

Fan, S., Wang, J., Yuan, R., Ma, Y., Meng, Q., Erdos, M. R., Pestell, R. G., Yuan, F., Auborn, K. J., Goldberg, I. D., & Rosen, E. M. (1999). BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science, 284, 1354–1356.PubMedCrossRef

63.

Zheng, L., Annab, L. A., Afshari, C. A., Lee, W. H., & Boyer, T. G. (2001). BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proceedings of the National Academy of Sciences of the United States of America, 98, 9587–9592.PubMedCrossRef

64.

Hu, Y., Ghosh, S., Amleh, A., Yue, W., Lu, Y., Katz, A., & Li, R. (2005). Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression. Oncogene, 24, 8343–8348.PubMedCrossRef

65.

Jones, L. P., Tilli, M. T., Assefnia, S., Torre, K., Halama, E. D., Parrish, A., Rosen, E. M., & Furth, P. A. (2008). Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer. Oncogene, 27, 794–802.PubMedCrossRef

66.

Li, W., Xiao, C., Vonderhaar, B. K., & Deng, C. X. (2007). A role of estrogen/ERalpha signaling in BRCA1-associated tissue-specific tumor formation. Oncogene, 26, 7204–7212.PubMedCrossRef

67.

Eisinger, F., Jacquemier, J., Nogues, C., Birnbaum, D., & Sobol, H. (1999). Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer, 85, 2291–2295.PubMedCrossRef

68.

Johannsson, O. T., Idvall, I., Anderson, C., Borg, A., Barkardottir, R. B., Egilsson, V., & Olsson, H. (1997). Tumour biological features of BRCA1-induced breast and ovarian cancer. European Journal of Cancer, 33, 362–371.PubMedCrossRef

69.

Karp, S. E., Tonin, P. N., Begin, L. R., Martinez, J. J., Zhang, J. C., Pollak, M. N., & Foulkes, W. D. (1997). Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer, 80, 435–441.PubMedCrossRef

70.

Foulkes, W. D., Metcalfe, K., Sun, P., Hanna, W. M., Lynch, H. T., Ghadirian, P., Tung, N., Olopade, O. I., Weber, B. L., McLennan, J., Olivotto, I. A., Begin, L. R., & Narod, S. A. (2004). Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 10, 2029–2034.CrossRef

71.

Hosey, A. M., Gorski, J. J., Murray, M. M., Quinn, J. E., Chung, W. Y., Stewart, G. E., James, C. R., Farragher, S. M., Mulligan, J. M., Scott, A. N., Dervan, P. A., Johnston, P. G., Couch, F. J., Daly, P. A., Kay, E., McCann, A., Mullan, P. B., & Harkin, D. P. (2007). Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. Journal of the National Cancer Institute, 99, 1683–1694.PubMedCrossRef

72.

Barone, I., Brusco, L., & Fuqua, S. A. (2010). Estrogen receptor mutations and changes in downstream gene expression and signaling. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 16, 2702–2708.CrossRef

73.

Cui, Y., Zhang, M., Pestell, R., Curran, E. M., Welshons, W. V., & Fuqua, S. A. (2004). Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen sensitivity. Cancer Research, 64, 9199–9208.PubMedCrossRef

74.

Herynk, M. H., & Fuqua, S. A. (2004). Estrogen receptor mutations in human disease. Endocrine Reviews, 25, 869–898.PubMedCrossRef

75.

Ma, Y., Fan, S., Hu, C., Meng, Q., Fuqua, S. A., Pestell, R. G., Tomita, Y. A., & Rosen, E. M. (2010). BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha. Molecular Endocrinology, 24, 76–90.PubMedCrossRef

76.

Kauff, N. D., Satagopan, J. M., Robson, M. E., Scheuer, L., Hensley, M., Hudis, C. A., Ellis, N. A., Boyd, J., Borgen, P. I., Barakat, R. R., Norton, L., Castiel, M., Nafa, K., & Offit, K. (2002). Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. The New England Journal of Medicine, 346, 1609–1615.PubMedCrossRef

77.

Bachelier, R., Li, C., Qiao, W., Furth, P. A., Lubet, R. A., & Deng, C. X. (2005). Effects of bilateral oophorectomy on mammary tumor formation in breast cancer associated gene 1 (Brca1) mutant mice. Oncology Reports, 14, 1117–1120.PubMed

78.

Ma, Y., Katiyar, P., Jones, L. P., Fan, S., Zhang, Y., Furth, P. A., & Rosen, E. M. (2006). The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Molecular Endocrinology, 20, 14–34.PubMedCrossRef

79.

Poole, A. J., Li, Y., Kim, Y., Lin, S. C., Lee, W. H., & Lee, E. Y. (2006). Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science, 314, 1467–1470.PubMedCrossRef

80.

Burga, L. N., Hu, H., Juvekar, A., Tung, N. M., Troyan, S. L., Hofstatter, E. W., & Wulf, G. M. (2011). Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice. Breast Cancer Research: BCR, 13, R30.PubMedCrossRef

81.

Rottenberg, S., Nygren, A. O., Pajic, M., van Leeuwen, F. W., van der Heijden, I., van de Wetering, K., Liu, X., de Visser, K. E., Gilhuijs, K. G., van Tellingen, O., Schouten, J. P., Jonkers, J., & Borst, P. (2007). Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 104, 12117–12122.PubMedCrossRef

82.

Shafee, N., Smith, C. R., Wei, S., Kim, Y., Mills, G. B., Hortobagyi, G. N., Stanbridge, E. J., & Lee, E. Y. (2008). Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Research, 68, 3243–3250.PubMedCrossRef

83.

Byrski, T., Huzarski, T., Dent, R., Gronwald, J., Zuziak, D., Cybulski, C., Kladny, J., Gorski, B., Lubinski, J., & Narod, S. A. (2009). Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Research and Treatment, 115, 359–363.PubMedCrossRef

84.

Bryant, H. E., & Helleday, T. (2004). Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents. Biochemical Society Transactions, 32, 959–961.PubMedCrossRef

85.

Dantzer, F., Schreiber, V., Niedergang, C., Trucco, C., Flatter, E., De La Rubia, G., Oliver, J., Rolli, V., Menissier-de Murcia, J., & de Murcia, G. (1999). Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie, 81, 69–75.PubMedCrossRef

86.

Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature, 434, 913–917.PubMedCrossRef

87.

Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., Martin, N. M., Jackson, S. P., Smith, G. C., & Ashworth, A. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434, 917–921.PubMedCrossRef

88.

De Soto, J. A., Wang, X., Tominaga, Y., Wang, R. H., Cao, L., Qiao, W., Li, C., Xu, X., Skoumbourdis, A. P., Prindiville, S. A., Thomas, C. J., & Deng, C. X. (2006). The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors. International Journal of Biological Sciences, 2, 179–185.PubMedCrossRef

89.

De Soto, J. A., & Deng, C. (2006). PARP-1 inhibitors, are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers? International Journal of Medical Sciences, 3, 117–123.PubMedCrossRef

90.

Rottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O., Zander, S. A., Derksen, P. W., de Bruin, M., Zevenhoven, J., Lau, A., Boulter, R., Cranston, A., O’Connor, M. J., Martin, N. M., Borst, P., & Jonkers, J. (2008). High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proceedings of the National Academy of Sciences of the United States of America, 105, 17079–17084.PubMedCrossRef

91.

Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O’Connor, M. J., Ashworth, A., Carmichael, J., Kaye, S. B., Schellens, J. H., & de Bono, J. S. (2009). Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. The New England Journal of Medicine, 361, 123–134.PubMedCrossRef

92.

Foulkes, W. D. (2004). BRCA1 functions as a breast stem cell regulator. Journal of Medical Genetics, 41, 1–5.PubMedCrossRef

93.

Somasundaram, V., & Srinivas, P. (2010). Insights into the targeted elimination of BRCA1-defective cancer stem cells. Medicinal Research Reviews, 32(5), 948–967.PubMedCrossRef

94.

Hakem, R., de la Pompa, J. L., Sirard, C., Mo, R., Woo, M., Hakem, A., Wakeham, A., Potter, J., Reitmair, A., Billia, F., Firpo, E., Hui, C. C., Roberts, J., Rossant, J., & Mak, T. W. (1996). The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell, 85, 1009–1023.PubMedCrossRef

95.

Liu, C. Y., Flesken-Nikitin, A., Li, S., Zeng, Y., & Lee, W. H. (1996). Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. Genes & Development, 10, 1835–1843.CrossRef

96.

Gowen, L. C., Johnson, B. L., Latour, A. M., Sulik, K. K., & Koller, B. H. (1996). Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nature Genetics, 12, 191–194.PubMedCrossRef

97.

Hohenstein, P., Kielman, M. F., Breukel, C., Bennett, L. M., Wiseman, R., Krimpenfort, P., Cornelisse, C., van Ommen, G. J., Devilee, P., & Fodde, R. (2001). A targeted mouse Brca1 mutation removing the last BRCT repeat results in apoptosis and embryonic lethality at the headfold stage. Oncogene, 20, 2544–2550.PubMedCrossRef

98.

Liu, X., Holstege, H., van der Gulden, H., Treur-Mulder, M., Zevenhoven, J., Velds, A., Kerkhoven, R. M., van Vliet, M. H., Wessels, L. F., Peterse, J. L., Berns, A., & Jonkers, J. (2007). Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 104, 12111–12116.PubMedCrossRef

99.

McCarthy, A., Savage, K., Gabriel, A., Naceur, C., Reis-Filho, J. S., & Ashworth, A. (2007). A mouse model of basal-like breast carcinoma with metaplastic elements. The Journal of Pathology, 211, 389–398.PubMedCrossRef

100.

Shakya, R., Szabolcs, M., McCarthy, E., Ospina, E., Basso, K., Nandula, S., Murty, V., Baer, R., & Ludwig, T. (2008). The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression. Proceedings of the National Academy of Sciences of the United States of America, 105, 7040–7045.PubMedCrossRef

101.

Mak, T. W., Hakem, A., McPherson, J. P., Shehabeldin, A., Zablocki, E., Migon, E., Duncan, G. S., Bouchard, D., Wakeham, A., Cheung, A., Karaskova, J., Sarosi, I., Squire, J., Marth, J., & Hakem, R. (2000). Brcal required for T cell lineage development but not TCR loci rearrangement. Nature Immunology, 1, 77–82.PubMedCrossRef

102.

Berton, T. R., Matsumoto, T., Page, A., Conti, C. J., Deng, C. X., Jorcano, J. L., & Johnson, D. G. (2003). Tumor formation in mice with conditional inactivation of Brca1 in epithelial tissues. Oncogene, 22, 5415–5426.PubMedCrossRef

103.

Chodankar, R., Kwang, S., Sangiorgi, F., Hong, H., Yen, H. Y., Deng, C., Pike, M. C., Shuler, C. F., Maxson, R., & Dubeau, L. (2005). Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells. Current Biology, 15, 561–565.PubMedCrossRef

104.

Quinn, B. A., Brake, T., Hua, X., Baxter-Jones, K., Litwin, S., Ellenson, L. H., & Connolly, D. C. (2009). Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53. PLoS One, 4, e8404.PubMedCrossRef

105.

Shakya, R., Reid, L. J., Reczek, C. R., Cole, F., Egli, D., Lin, C. S., deRooij, D. G., Hirsch, S., Ravi, K., Hicks, J. B., Szabolcs, M., Jasin, M., Baer, R., & Ludwig, T. (2011). BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity. Science, 334, 525–528.PubMedCrossRef

106.

Pulvers, J. N., & Huttner, W. B. (2009). Brca1 is required for embryonic development of the mouse cerebral cortex to normal size by preventing apoptosis of early neural progenitors. Development, 136, 1859–1868.PubMedCrossRef

107.

Teoh, H., Quan, A., Creighton, A. K., Annie Bang, K. W., Singh, K. K., Shukla, P. C., Gupta, N., Pan, Y., Lovren, F., Leong-Poi, H., Al-Omran, M., & Verma, S. (2012). BRCA1 gene therapy reduces systemic inflammatory response and multiple organ failure and improves survival in experimental sepsis. Gene Therapy. doi:10.1038/gt.2011.214.

108.

Yang, Y., Swaminathan, S., Martin, B. K., & Sharan, S. K. (2003). Aberrant splicing induced by missense mutations in BRCA1: clues from a humanized mouse model. Human Molecular Genetics, 12, 2121–2131.PubMedCrossRef

109.

Drost, R., Bouwman, P., Rottenberg, S., Boon, U., Schut, E., Klarenbeek, S., Klijn, C., van der Heijden, I., van der Gulden, H., Wientjens, E., Pieterse, M., Catteau, A., Green, P., Solomon, E., Morris, J. R., & Jonkers, J. (2011). BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell, 20, 797–809.PubMedCrossRef

110.

Kim, E. H., Deng, C., Sporn, M. B., Royce, D. B., Risingsong, R., Williams, C. R., & Liby, K. T. (2012). CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice. Cancer Prevention Research (Philadelphia, Pa.), 5, 89–97.CrossRef

111.

Kim, E. H., Deng, C. X., Sporn, M. B., & Liby, K. T. (2011). CDDO-imidazolide induces DNA damage, G2/M arrest and apoptosis in BRCA1-mutated breast cancer cells. Cancer Prevention Research (Philadelphia, Pa.), 4, 425–434.CrossRef

112.

Tominaga, Y., Wang, A., Wang, R. H., Wang, X., Cao, L., & Deng, C. X. (2007). Genistein inhibits Brca1 mutant tumor growth through activation of DNA damage checkpoints, cell cycle arrest, and mitotic catastrophe. Cell Death and Differentiation, 14, 472–479.PubMedCrossRef

113.

Wang, R. H., Zheng, Y., Kim, H. S., Xu, X., Cao, L., Luhasen, T., Lee, M. H., Xiao, C., Vassilopoulos, A., Chen, W., Gardner, K., Man, Y. G., Hung, M. C., Finkel, T., & Deng, C. X. (2008). Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Molecular Cell, 32, 11–20.PubMedCrossRef

114.

Zander, S. A., Kersbergen, A., van der Burg, E., de Water, N., van Tellingen, O., Gunnarsdottir, S., Jaspers, J. E., Pajic, M., Nygren, A. O., Jonkers, J., Borst, P., & Rottenberg, S. (2010). Sensitivity and acquired resistance of BRCA1; p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Cancer Research, 70, 1700–1710.PubMedCrossRef

Title: Mouse models of BRCA1 and their application to breast cancer research
Authors: Jennifer Dine
Chu-Xia Deng
Publication date: 01-06-2013
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 1-2/2013
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-012-9403-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1-2/2013

Tumor dormancy and the neuroendocrine system: an undisclosed connection?

Targeting the Ras–ERK pathway in pancreatic adenocarcinoma

Erratum to: The role of pharmacogenomics in metastatic renal cell carcinoma

Hide and seek: tell-tale signs of breast cancer lurking in the blood

Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis

Reconstructing skin cancers using animal models

Keynote webinar | Spotlight on antibody–drug conjugates in cancer